10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELEVANCE HEALTH, INC. | |||
Ticker: ELV Fiscal Year: 2012 | |||
Consolidated Statements Of Cash Flows | |||
Period Ending Dec 31, 2012 10-K (Filed: Feb 22, 2013) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | |
| Operating activities | |||
| Net income | $ 2,655,500 | 2,646,700 | 2,887,100 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Net realized gains/losses on investments | (334,900) | (235,100) | (194,100) |
| Other-than-temporary impairment losses recognized in income | 37,800 | 93,300 | 39,400 |
| Loss on disposal of assets | 4,700 | 3,300 | 1,900 |
| Deferred income taxes | 127,500 | 74,300 | 101,800 |
| Amortization, net of accretion | 633,600 | 541,500 | 497,700 |
| Impairment of goodwill and other intangible assets | 0 | 0 | 21,100 |
| Depreciation expense | 107,100 | 95,700 | 103,100 |
| Impairment of property and equipment | 66,800 | 0 | 95,300 |
| Share-based compensation | 146,500 | 134,800 | 136,000 |
| Excess tax benefits from share-based compensation | (28,800) | (42,200) | (28,100) |
| Changes in operating assets and liabilities, net of effect of business combinations: | |||
| Receivables, net | 189,900 | (401,800) | 109,700 |
| Other invested assets | (38,900) | (8,900) | 5,100 |
| Other assets | 79,200 | (259,200) | (320,100) |
| Policy liabilities | (53,700) | 978,000 | (330,700) |
| Unearned income | (193,700) | 35,100 | (158,600) |
| Accounts payable and accrued expenses | (406,500) | (208,700) | (58,200) |
| Other liabilities | (132,800) | (13,600) | (208,400) |
| Income taxes | (73,900) | (44,600) | (1,239,800) |
| Other, net | (40,800) | (14,200) | (43,500) |
| Net cash provided by operating activities | 2,744,600 | 3,374,400 | 1,416,700 |
| Investing activities | |||
| Purchases of fixed maturity securities | (15,040,400) | (11,914,800) | (10,567,200) |
| Proceeds from fixed maturity securities: | |||
| Sales | 13,675,900 | 10,446,200 | 7,215,100 |
| Maturities, calls and redemptions | 1,781,500 | 1,891,300 | 3,321,700 |
| Purchases of equity securities | (292,600) | (355,600) | (350,900) |
| Proceeds from sales of equity securities | 422,700 | 287,400 | 197,900 |
| Purchases of other invested assets | (303,700) | (207,900) | (91,400) |
| Proceeds from sales of other invested assets | 35,500 | 29,400 | 34,500 |
| Changes in securities lending collateral | 307,900 | 28,900 | (504,800) |
| Purchases of subsidiaries, net of cash acquired | (4,597,000) | (600,000) | (300) |
| Purchases of property and equipment | (544,900) | (519,500) | (451,400) |
| Proceeds from sales of property and equipment | 400 | 3,700 | 800 |
| Other, net | 3,100 | (31,100) | (75,500) |
| Net cash (used in) provided by investing activities | (4,551,600) | (942,000) | (1,271,500) |
| Financing activities | |||
| Net proceeds from (repayments of) commercial paper borrowings | (229,000) | 463,600 | (164,400) |
| Proceeds From Issuance Of Long Term Debt | 6,468,900 | 1,097,400 | 1,088,500 |
| Repayments of long-term borrowings | (1,251,300) | (705,100) | (481,700) |
| Proceeds from short-term borrowings | 642,000 | 100,000 | 100,000 |
| Repayments of short-term borrowings | (492,000) | (100,000) | 0 |
| Changes in securities lending payable | (307,800) | (29,000) | 504,900 |
| Changes in bank overdrafts | (17,600) | 264,300 | (28,000) |
| Repurchase and retirement of common stock | (2,496,800) | (3,039,800) | (4,360,300) |
| Cash dividends | (367,100) | (357,800) | 0 |
| Proceeds from exercise of employee stock options | 110,800 | 245,000 | 143,600 |
| Excess tax benefit from share baed compensation | 28,800 | 42,200 | 28,100 |
| Net cash used in financing activities | 2,088,900 | (2,019,200) | (3,169,300) |
| Effect of foreign exchange rates on cash and cash equivalents | 1,100 | (400) | (3,200) |
| Change in cash and cash equivalents | 283,000 | 412,800 | (3,027,300) |
| Cash and cash equivalents at beginning of year | 2,201,600 | 1,788,800 | |
| Cash and cash equivalents at end of year | 2,484,600 | 2,201,600 | 1,788,800 |
| External Links | |
| ELEVANCE HEALTH, INC. (ELV) Fiscal Year 2012 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |